Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,145 JPY | +0.10% | +0.19% | +8.21% |
Apr. 09 | H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy | MT |
Mar. 29 | Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation | MT |
Business Summary
Number of employees: 9,421
Sales per Business
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
System Integration
64.5
%
| 541,671 | 62.9 % | 630,185 | 64.5 % | +16.34% |
Service and Support
35.5
%
| 319,350 | 37.1 % | 347,185 | 35.5 % | +8.72% |
Sales per region
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Japan
100.0
%
| 861,022 | 100.0 % | 977,370 | 100.0 % | +13.51% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Yuji Otsuka
PSD | President | 70 | 81-10-31 |
Koichi Hisano
CMP | Compliance Officer | - | - |
Minoru Sakurai
CTO | Chief Tech/Sci/R&D Officer | 67 | 79-02-28 |
Hironobu Saito
ADM | Chief Administrative Officer | 74 | 68-07-31 |
Hironobu Tsurumi
BRD | Director/Board Member | 68 | 79-02-28 |
Katsuhiro Yano
BRD | Director/Board Member | 68 | 79-02-28 |
Director/Board Member | 73 | 73-02-28 | |
Director/Board Member | 71 | 76-02-29 | |
Tatsumi Murata
AUD | Comptroller/Controller/Auditor | - | - |
Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Yuji Otsuka
PSD | President | 70 | 81-10-31 |
Director/Board Member | 71 | 76-02-29 | |
Director/Board Member | 73 | 73-02-28 | |
Katsuhiro Yano
BRD | Director/Board Member | 68 | 79-02-28 |
Hironobu Saito
ADM | Chief Administrative Officer | 74 | 68-07-31 |
Tetsuo Saito
BRD | Director/Board Member | 70 | 16-02-29 |
Hironobu Tsurumi
BRD | Director/Board Member | 68 | 79-02-28 |
Jiro Makino
BRD | Director/Board Member | 70 | 04-02-29 |
Minoru Sakurai
CTO | Chief Tech/Sci/R&D Officer | 67 | 79-02-28 |
Makiko Hamabe
BRD | Director/Board Member | 59 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 380,004,240 | 220,756,312 ( 58.09 %) | 802,000 ( 0.2111 %) | 58.09 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
PERSOL HOLDINGS CO.,LTD. 1.29% | 30,000,000 | 1.29% | 42,320,400 $ |
AVILEN INC. 18.84% | 1,140,000 | 18.84% | 20,299,980 $ |
OTSUKA CORPORATION 0.21% | 802,200 | 0.21% | 16,945,609 $ |
SIOS CORPORATION 17.95% | 1,593,300 | 17.95% | 7,106,134 $ |
GIG WORKS INC. 4.90% | 1,080,000 | 4.90% | 4,188,845 $ |
RICOH COMPANY, LTD. 0.07% | 439,885 | 0.07% | 3,928,142 $ |
100,000 | 0.02% | 2,991,840 $ | |
382,204 | 0.03% | 1,944,039 $ | |
13,100 | 0.02% | 1,510,423 $ | |
NIHON KNOWLEDGE CO,LTD. 9.74% | 134,000 | 9.74% | 1,344,028 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
ReCor Medical, Inc.
ReCor Medical, Inc. Pharmaceuticals: MajorHealth Technology ReCor Medical, Inc. develops novel therapeutic ultrasound catheter technologies The firm develops a therapeutic non-focused ultrasound system for performing renal denervation in patients with resistant hypertension. The company was founded by Mano Iyer and Jacques Seguin in July 2009 and is headquartered in Palo Alto, CA. |
Pharmaceuticals: Major
|
Sector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.21% | 7.7B | |
-6.95% | 31.72B | |
-0.23% | 15.08B | |
-10.59% | 8.57B | |
+5.19% | 5.01B | |
-45.35% | 4.49B | |
+12.79% | 3.06B | |
+6.31% | 2.41B | |
-15.24% | 2.31B | |
-8.87% | 1.12B |
- Stock Market
- Equities
- 4768 Stock
- Company Otsuka Corporation